By InvitationNot Applicable

ROSE for Improved Molecular Marker Testing Via EBUS

United States349 participantsStarted 2021-05-14

Plain-language summary

This research study is being done to compare two ways to conduct bronchoscopic biopsy of lymph nodes and other structures in the chest (i.e. the presence or absence of an on-site cytotechnologist performing a limited microscopic evaluation to provide non-binding feedback on specimen adequacy in real time during the procedure).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Inpatients or outpatients \>18 years old * Capable of informed consent * Known or suspected non-small cell lung cancer (NSCLC) * Referred to the interventional pulmonary team at Johns Hopkins Hospital (JHH), Johns Hopkins Bayview Medical Center (JHBMC), or other participating sites for tissue sampling of a hilar/mediastinal lymph node or another lesion accessible by convex-probe (CP) EBUS Exclusion Criteria: * Refuse participation * Standard contraindications to EBUS and bronchoscopy in general: bleeding disorders, antiplatelet or anticoagulant usage, high fraction of inspired oxygen (FiO2) requirement, and clinical instability * Pregnant women * Cytotechnologist not available at the time of screening, enrollment, or randomization

What they're measuring

Percentage of NGS biomarker testing attempts

Timeframe: within 60 days of procedure

Trial details

NCT IDNCT04945317

SponsorJohns Hopkins University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-31

View on ClinicalTrials.gov More Non-small Cell Lung Cancer (NSCLC) trials